GlassScriptPhysician profile
Michael James Abbott
NPI 1942815915
$2,596.16
in general payments reported to CMS, 2019-2025
17 companies · $560 in 2025
The $560 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.00 · 2022: $254 · 2023: $885 · 2024: $849 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,292.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $650.80 | 2023-2025 | Lifevest |
| Amgen INC. | $335.22 | 2022-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.96 | 2024-2025 | Jardiance |
| Pfizer INC. | $267.52 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $259.89 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $165.44 | 2021-2024 | Camzyos, Eliquis |
| Shockwave Medical, INC | $104.59 | 2023 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astrazeneca Pharmaceuticals LP | $87.24 | 2022-2025 | Farxiga, Wainua |
| Lexicon Pharmaceuticals, INC. | $81.16 | 2023 | Inpefa |
| Heartflow, INC. | $72.74 | 2025 | |
| Janssen Pharmaceuticals, INC | $70.53 | 2024 | Xarelto |
| Terumo Medical Corporation | $58.15 | 2022-2024 | Glidewire, Tr Band, Angio-Seal |
| Kiniksa Pharmaceuticals International, Plc | $57.69 | 2024 | Arcalyst |
| Chiesi USA, INC. | $42.97 | 2022 | |
| Scpharmaceuticals INC. | $21.84 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $18.72 | 2025 | Wegovy |
| Kiniksa Pharmaceuticals, LTD. | $14.70 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Abbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.